Stay updated on Dupilumab in AFRS Clinical Trial

Sign up to get notified when there's something new on the Dupilumab in AFRS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Dupilumab in AFRS Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The record now presents details of the completed Phase 3 dupilumab trial for allergic fungal rhinosinusitis, including eligibility, study design, outcomes, and results-related resources. It also includes study documents, a publication, and information about participant-data sharing.
    Difference
    81%
    Check dated 2026-11-08T14:16:24.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0; the study page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T15:18:40.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A sitewide NIH banner announces updates and FAQs about using “Super Intelligence” in place of “Artificial Intelligence” during the transition.
    Difference
    1%
    Check dated 2026-10-25T16:12:12.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The clinical trial details have been replaced by a 403 Forbidden message, leaving the study record unavailable on the page.
    Difference
    19%
    Check dated 2026-10-18T22:13:09.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the dupilumab study in allergic fungal rhinosinusitis is displayed, including its eligibility criteria, study design, outcome measures, locations, and supporting documents.
    Difference
    82%
    Check dated 2026-10-11T22:01:47.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study details and navigation with an access-denied screen. This indicates a server-side access issue or restriction that prevents users from viewing the trial record.
    Difference
    19%
    Check dated 2026-09-20T20:47:51.000Z thumbnail image

Stay in the know with updates to Dupilumab in AFRS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Dupilumab in AFRS Clinical Trial page.